Annovis Bio WKN: A2PNH2 ISIN: US03615A1088 Kürzel: ANVS Forum: Aktien User: Schorsch11

https://www.reddit.com/r/Annovis/comments/15cqx6o/anvs_amyotrophic_lateral_sclerosis/?utm_source=share&utm_medium=ios_app&utm_name=ioscss&utm_content=1&utm_term=3

https://www.reddit.com/r/Annovis/comments/15c03wk/anvs_ad_phase_iii_study_update/?utm_source=share&utm_medium=ios_app&utm_name=ioscss&utm_content=1&utm_term=3

Keine wirklich neuen Infos aber trotzdem ganz nett, die neue IR-News zu lesen: "Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference" Link dazu: https://irpages2.eqs.com/websites/annovis/English/431010/us-press-release.html?airportNewsID=95746e43-00bf-47ad-a113-b5493bfdfa62

Die 20 oder 30€ hätten wir schon längst hinter uns lassen müssen. Keine Ahnung wo es hier klemmt

Ich verstehe es auch nicht …

Cassava hat ja nicht wirklich überzeugt und ist trotzdem bei 1 Milliarde und wir beim 1/10 lächerlich

Was glaubt ihr passiert hir bald?

https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=ANVS

Link: https://www.linkedin.com/pulse/qa-maria-l-maccecchini-phd?trk=public_profile_article_view

Maria L. Maccecchini, PhD Founder, President & Chief Executive Officer… Veröffentlicht: 29. Juni 2023 "We are happy to have received feedback on the news release we sent out this week about our filing of a new composition of matter patent. We’ve received some questions, so here are a few points we hope will clarify any confusion. Of course, feel free to reach out to me directly for further explanation. Thank you; we appreciate your interest in our work! With this patent filing, is Annovis changing drugs? No. The patent filing is for a new form of buntanetap - a crystalline form, called ANVS402, which offers structural advantages over the previous form. But the new form is the same essential drug. What is the difference between ANVS301, ANVS401, and ANVS402? ANVS301 is a totally different molecule with a different mechanism of action being studied for advanced Alzheimer’s disease. ANVS401, also previously known as posiphen, is the same as buntanetap. ANVS402 has shown equal effectiveness and safety in mice compared to its non-crystalline form. However, the crystalline form provides additional advantages in terms of stability, purity, and half-life, as well as increased duration of patent protection. For consistency, all ongoing studies will continue to use the same drug that was used at the beginning of the trial. Although, going forward, we will conduct future studies with ANVS402. Please elaborate on the bridge trial mentioned in the release. Now that we have convincing mouse data, we will propose a short, well-documented bridging study in humans to the FDA. We will wait for their feedback and proceed accordingly. The bridge study is designed to expedite the transition from ANVS401 to ANVS402. The bridge study depends on the similarity or difference in the performance and efficacy of ANVS401 and ANVS402 in trial patients as measured through blood samples. If approved, how will the new composition of matter patent affect the timing of current clinical trials? The patent will not delay individual clinical trials but will rather enable Annovis to continue moving forward more expeditiously with the development of novel drugs for neurodegenerative diseases. "

Auf Linkedin wurde ein Q&A mit Antworten zu Fragen zur aktuellen Pressemitteilung veröffentlicht:

Es ist echt komisch , so viel gute news und nichts bewegt den Kurs….

Macht für mich persönlich nicht unbedingt sehr viel Sinn, aber vielleicht bin ich da nur zu sehr 'Chemiker' in der Hinsicht 😅 Wir werden sehen... Vermutlich einfach nur, um die geforderten Qualitätskontrollen besser zu erreichen und um mit dieser Umgehung vielleicht sogar mit viel Glück einen längeren Patent-Schutz zu bekommen^^

https://irpages2.eqs.com/websites/annovis/English/431010/us-press-release.html?airportNewsID=c8f2bb8f-32ad-46c1-b2c7-9d7347ff0dfb

Annovis will wohl seine Formulierung von Buntanetap leicht ändern (kristallin vs ehemals amorph) - Anfang 2024 soll dafür noch eine weitere 'Bridging-Studie' geplant sein...

Im Interview der CEO https://www.youtube.com/watch?app=desktop&v=WIAd-O4CdPs ab 16:20 wird deutlich, dass die P3 Studie wohl ziemlich positiv zu laufen scheint, CEO: 'something like 23 or so have finished the six months and they all told the doctor they feel a lot better' ! Das ist zwar keine statistisch signifikante Aussage (nur die zählt!), aber es ist schon sehr bemerkenswert wie der Markt und Analysten solche Aussagen zu einer bald abschließenden P3 (zumindest noch) zu ignorieren scheinen, aber ... ich habe Geduld 🙂